OncoMatch/Clinical Trials/NCT06687876
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
Is NCT06687876 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Metformin for oesophageal adenocarcinoma.
Treatment: Metformin — The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage <T4B
Surgical resectable (<T4b, N0 or N+, M0)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Previous systemic therapy or radiotherapy on the oesophagus
Cannot have received: radiation therapy
Previous systemic therapy or radiotherapy on the oesophagus
Cannot have received: systemic therapy
Previous systemic therapy for other forms of cancer within the last six months
Lab requirements
Blood counts
Absolute Neutrophil Count ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 5.6 mmol
Kidney function
Creatinine clearance (Cockroft) > 30 ml/min
Liver function
Total bilirubin ≤ 1.5 x upper normal limit
Adequate hematological, renal and hepatic functions defined as: Absolute Neutrophil Count ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 5.6 mmol; Total bilirubin ≤ 1.5 x upper normal limit; Creatinine clearance (Cockroft) > 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify